Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia Clin Transl Sci. 2024;17:e70065. Vaddady P, Smania G, Nakayama S, Inoue H, Kurumaddali A, Abutarif M, Zheng M. JournalOncologyPharmacometricsRegulatory interactions Pharmetheus Affiliates Principal Director, MIDD Consultant Giovanni Smania See bio Director, Quality Control & Medical Writing Consultant Christina Pentafragka See bio Connected publication Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia